CN101449708B - Infant milk powder added with biostime and preparation method thereof - Google Patents
Infant milk powder added with biostime and preparation method thereof Download PDFInfo
- Publication number
- CN101449708B CN101449708B CN2008102498088A CN200810249808A CN101449708B CN 101449708 B CN101449708 B CN 101449708B CN 2008102498088 A CN2008102498088 A CN 2008102498088A CN 200810249808 A CN200810249808 A CN 200810249808A CN 101449708 B CN101449708 B CN 101449708B
- Authority
- CN
- China
- Prior art keywords
- gram
- parts
- grams
- milk powder
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 61
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 17
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 57
- 235000013336 milk Nutrition 0.000 claims abstract description 48
- 239000008267 milk Substances 0.000 claims abstract description 48
- 210000004080 milk Anatomy 0.000 claims abstract description 48
- 235000018291 probiotics Nutrition 0.000 claims abstract description 37
- 239000006041 probiotic Substances 0.000 claims abstract description 35
- 230000000529 probiotic effect Effects 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000005862 Whey Substances 0.000 claims abstract description 11
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 11
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 6
- 239000008158 vegetable oil Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002131 composite material Substances 0.000 claims description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 21
- 239000011707 mineral Substances 0.000 claims description 21
- 235000010755 mineral Nutrition 0.000 claims description 21
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 20
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 11
- 244000068988 Glycine max Species 0.000 claims description 11
- 235000010469 Glycine max Nutrition 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 229920001542 oligosaccharide Polymers 0.000 claims description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims description 11
- 229920001202 Inulin Polymers 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 10
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 10
- 235000013734 beta-carotene Nutrition 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 10
- 229960002747 betacarotene Drugs 0.000 claims description 10
- 235000021552 granulated sugar Nutrition 0.000 claims description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 10
- 229940029339 inulin Drugs 0.000 claims description 10
- 229940039696 lactobacillus Drugs 0.000 claims description 10
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 10
- 229960003080 taurine Drugs 0.000 claims description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 10
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 8
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 7
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 7
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 208000007976 Ketosis Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 150000002584 ketoses Chemical class 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000186012 Bifidobacterium breve Species 0.000 claims description 4
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 3
- 239000004225 ferrous lactate Substances 0.000 claims description 3
- 235000013925 ferrous lactate Nutrition 0.000 claims description 3
- 229940037907 ferrous lactate Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 239000011772 phylloquinone Substances 0.000 claims description 3
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 3
- 239000001230 potassium iodate Substances 0.000 claims description 3
- 235000006666 potassium iodate Nutrition 0.000 claims description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 3
- 229940093930 potassium iodate Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000009461 vacuum packaging Methods 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 27
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 206010012735 Diarrhoea Diseases 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 9
- 241000702670 Rotavirus Species 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 235000019722 synbiotics Nutrition 0.000 abstract description 2
- 230000001965 increasing effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 16
- 239000000306 component Substances 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 235000019483 Peanut oil Nutrition 0.000 description 8
- 229960001231 choline Drugs 0.000 description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000312 peanut oil Substances 0.000 description 8
- 208000019637 Infantile Diarrhea Diseases 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229910021647 smectite Inorganic materials 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Abstract
The invention discloses an infant milk power added with synbiotics, comprising the following components: fresh milk 40-68 gram; demineralized whey powder 15-34 gram; granulated sugar3-6 graml; vegetable oil 4-8 gram; compound prebiotics 0.4-20 gram; compound probiotic 1.0*10<5>-1.0*10<11> cfu. The inventive infant milk power can be ysed for building advantages of beneficial bacterium when a newborn infant starts colony valuation. Through adding probiotic, the number of probiotic is advanced to increase in a short time, through adding prebiotics having selectively increasing effect on probiotic, the added probiotic is performed with fast field setting, thereby maintaining advantages of probiotic in intestinal flora. The invention also markedly relieves diarrhoetic symptoms, and has definite treatment effect on diarrhea caused by rotavirus.
Description
Technical field
The present invention relates to a kind of add symphysis unit be suitable for milk powder of infant and preparation method thereof, belong to technical field of processing dairy products.
Background technology
As everyone knows, the baby is from being born by 3 years old, it is the most important stage of growing in life, really all babies being used breast milk is best nurture mode, yet often exist owing to breast milk not enough or other reason can not breastfeeding situation in the reality, at this moment just can only select high-quality baby formula milk powder.Existing baby formula milk powder is a lot, yet for the infant better grows, need continually develop new formula milk.
The life that breeds in mother uterus is integral asepsis, yet is born back first day, just can find the existence of bacterium in baby's ight soil, and being born back three days total bacteria counts can be up to 10
11Cfu/g is so the activity of bacterium in human body is very noticeable.
According to the interaction property of gut flora, enteric bacteria can be divided into beneficial bacterium, harmful bacterium and two-way bacterium three major types to body.Probio has the gut flora of improvement structure, suppresses pathogen, eliminates carcinogen, improves the immunity of organism factor, reduces physiological functions such as cholesterol.Usually, flora in the enteron aisle is to maintain certain balance, yet, situations such as antibiotic, diarrhoea constipation are drunk, are used in disadvantaged group (the elderly, infant), irregular, the frequent smoking of living and diet, the quantity of probio is destroyed, thereby need take measures, recover the superiority of beneficial bacterium.
Prebiotics is meant not the food component that can be digested by digestive juice, and it can enter large intestine, is absorbed by beneficial bacterium specific in the large intestine, promotes the growth of beneficial bacterium, thereby promotes human beings'health.Present prebiotics typically refers to compound sugar, mainly contains soyabean oligosaccharides, FOS, galactooligosaccharide, xylo-oligosaccharide, inulin etc.
Symphysis unit becomes Synbiotics again, is meant the combination preparation of probio and prebiotics, both can bring into play the physiological bacterial activity of probio, optionally increases the quantity of probio again fast, makes the effect of probio more remarkable and lasting.
The seventies in 20th century, Australian scientist has found very easily to cause " rotavirus " of infantile diarrhea.In China, children below 5 years old on average suffer from diarrhoea 11 times for each person every year, and wherein the infantile diarrhea that is caused by rotavirus is the most common, also the most serious.Annual nearly 900,000 infants in the whole world die from rotavirus infection diarrhoea.It is reported, the intestinal flora imbalance is the one of the main reasons that causes diarrhoea, and by observing, breastfeeding infantile diarrhea incidence is starkly lower than the infant of NBF, its main cause be exactly in breastfeeding infant's enteron aisle the quantity of Bifidobacterium more than the infant of NBF, thereby alleviated the infringement of rotavirus to body.Therefore, can predict, be chosen in the baby milk powder add an amount of, effectively probio will obviously alleviate the infringement of rotavirus to the infant.
No matter in sum, provide a kind of baby milk powder that adds symphysis unit, be to recovering, keep the superiority of profitable strain in the enteron aisle, still to the prevention rotavirus, all having important function and significance.In the prior art, add prebiotics or probio in the dairy produce bibliographical information though have, its effect is all general, and specific aim is not strong.
Summary of the invention
At above-mentioned prior art, the invention provides a kind of baby milk powder that adds symphysis unit and preparation method thereof.
A kind of baby milk powder that adds symphysis unit comprises following component: fresh milk, 40～68 grams; Desalted whey powder, 15～37 grams; Granulated sugar, 3～6 grams; Vegetable oil, 4～8 grams; Complex prebiotics, 0.4～20 gram; Compound probiotic 1.0 * 10
5～1.0 * 10
14Cfu.
Described fresh milk can be milk, goat milk; The form of fresh milk can be a liquid milk, also can be the milk powder that is directly dusted and obtained by liquid milk for convenience of transportation.The preferred peanut oil of described vegetable oil, olive oil, corn wet goods are rich in the vegetable oil of unrighted acid.
The baby milk powder of described interpolation symphysis unit also comprises following component: B B-complex, 0.023 gram; Composite mineral matter, 0.5 gram; Nucleotides, 0.05 gram; Taurine, 0.04 gram; DHA, 0.15 gram; Arachidonic acid, 0.1 gram; Lecithin, 0.2 gram; Beta carotene, 0.14 gram.
The content of described complex prebiotics is 2～10 grams.
Described complex prebiotics is a kind of or several arbitrary proportions combination in oligoisomaltose, FOS, xylo-oligosaccharide, galactooligosaccharide, chitosan oligomer, soyabean oligosaccharides, inulin, the milk ketose; The preferred combination of compound sugar more than three kinds.
Described compound probiotic is a kind of or several arbitrary proportions combination in bifidobacterium strains, lactobacillus strains, streptococcus bacterial strain, lactococcus bacterial strain, the Bacillus strain.
Described compound probiotic is the combination of bifidobacterium strains and lactobacillus strains.
Described bifidobacterium strains is bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium longum or bifidobacterium breve; Described lactobacillus strains is lactobacillus bulgaricus, lactobacillus acidophilus, lactobacillus thermophilus or Lactobacillus casei.
Described B B-complex is composed of the following components: vitamin A, 4 grams; Vitamin D, 2 grams; Vitamin E, 0.1 gram; Vitamin K
1, 0.035 gram; Cobastab
1, 0.6 gram; Cobastab
2, 0.8 gram; Cobastab
6, 0.35 gram; Cobastab
12, 0.015 gram; Vitamin C, 2 grams; Niacinamide usp, 8 grams; Folic acid, 0.08 gram; Calcium pantothenate, 5 grams; Biotin, 0.02 gram.
Described composite mineral matter is composed of the following components: ferrous lactate, 50 grams; Zinc lactate, 10 grams; Copper sulphate, 2 grams; Potassiumiodate, 0.13 gram; Calcium carbonate, 437.7 grams; Manganese sulfate, 0.17 gram.
A kind of preparation method who adds the baby milk powder of symphysis unit, step is: mix other components except that compound probiotic, B B-complex, get mixed solution, use high pressure homogenizer under 10～20MPa, to carry out homogeneous then, carry out spray-drying or freeze drying then, get powder product, add compound probiotic, B B-complex then, mixing, vacuum packaging promptly gets milk powder.
Milk powder of the present invention also can adopt other any suitable methods to process.
Baby formula milk powder of the present invention, when can be used for newborn infants and beginning the bacterium colony definite value, the foundation of beneficial bacterium advantage.By adding probio, increase that can short time internal stimulus beneficial bacterium quantity, and, can make the quick field planting of probio of interpolation by adding prebiotics to the selective value-added effect of probio, keep the advantage of beneficial bacterium at gut flora.
After the infant taking symphysis unit prescription milk powder of diarrhoea takes place, by observing, the obvious symptom of alleviating diarrhoea, and the diarrhoea that rotavirus causes had certain result of treatment.
At present, life usually needs usually to kill pathogenic bacteria in the body by taking antibiosis after being ill, still, after administration of antibiotics, because antibiotic does not have identity, can kill harmful bacterium in the enteron aisle and one of beneficial bacterium, the quantity of the flora in the enteron aisle is sharply reduced.In the infant of administration of antibiotics, take symphysis unit, can recover the balance of flora in the enteron aisle, and beneficial bacterium is had more obvious value-added effect, can strengthen beneficial bacterium superiority in the flora in enteron aisle.
The symphysis unit that adds among the present invention is the best of breed that draws by behind the verification experimental verification repeatedly for the organic assembling of compound probiotic and complex prebiotics, and its effect that plays not is the simple superposition of each single material, but organically combination.Also added B B-complex, composite mineral matter and other nutriment in the milk powder of the present invention, can provide comprehensive nutrition to the infant.Added the vegetable oil that peanut oil, olive oil, corn wet goods are rich in unrighted acid, can increase the content of unrighted acid and essential fatty acids linoleic in the product, infant's brain development has been had good effect.Added essential fatty acids such as DHA, ARA, also had nutriments such as lecithin, nucleotides, be beneficial to the growth of infant's brain cell, very big benefit has been arranged improving baby's memory.
The specific embodiment
The present invention is further illustrated with the test example below in conjunction with embodiment:
Embodiment 1: prepare a kind of baby milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 47g
Desalted whey powder 36g
Granulated sugar 5g
Peanut oil 4g
Complex prebiotics 10g
Compound probiotic 1.0 * 10
8Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: oligoisomaltose: xylo-oligosaccharide: gossypose=10: 3: 5.
The composition weight proportioning of compound probiotic is: bifidobacterium infantis: bifidobacterium adolescentis: lactobacillus acidophilus=3: 2: 2.
The prescription of B B-complex is: vitamin A, 4g; Vitamin D, 2g; Vitamin E, 0.1g; Vitamin K
1, 0.035g; Cobastab
1, 0.6g; Cobastab
2, 0.8g; Cobastab
6, 0.35g; Cobastab
12, 0.015g; Vitamin C, 2g; Niacinamide usp, 8g; Folic acid, 0.08g; Calcium pantothenate, 5g; Biotin, 0.02g.
The prescription of composite mineral matter is: ferrous lactate, 50g; Zinc lactate, 10g; Copper sulphate, 2g; Potassiumiodate, 0.13g; Calcium carbonate, 437.7g; Manganese sulfate, 0.17g.
Preparation technology is: mix other components except that compound probiotic, B B-complex, get mixed solution, use high pressure homogenizer to carry out homogeneous then under 10～20MPa, carry out spray-drying then, get powder product, add compound probiotic, B B-complex then, mixing, vacuum packaging.
Embodiment 2: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 62g
Desalted whey powder 16g
Granulated sugar 6g
Olive oil 7g
Complex prebiotics 4g
Compound probiotic 1.0 * 10
12Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: soyabean oligosaccharides: xylo-oligosaccharide: gossypose=10: 2: 5.
The composition weight proportioning of compound probiotic is: bifidobacterium infantis: bifidobacterium adolescentis: lactobacillus acidophilus: lactobacillus thermophilus=3: 3: 2: 1.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 3: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 55g
Desalted whey powder 24g
Granulated sugar 5g
Corn oil 6g
Complex prebiotics 17g
Compound probiotic 1.0 * 10
10Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: soyabean oligosaccharides: FOS: xylo-oligosaccharide: gossypose=8: 5: 2: 5.
The composition weight proportioning of compound probiotic is: bifidobacterium infantis: bifidobacterium longum: lactobacillus acidophilus=3: 2: 2.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 4: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 50g
Desalted whey powder 25g
Granulated sugar 5g
Peanut oil 4g
Complex prebiotics 10g
Compound probiotic 1.0 * 10
6Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g.
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: soyabean oligosaccharides: FOS: xylo-oligosaccharide: gossypose=10: 5: 2: 5.
The composition weight proportioning of compound probiotic is: bifidobacterium infantis: bifidobacterium adolescentis: lactobacillus acidophilus=3: 2: 2.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 5: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Goat milk (material of giving money as a gift) 40g
Desalted whey powder 15g
Granulated sugar 3g
Peanut oil 4g
Complex prebiotics 0.4g
Compound probiotic 1.0 * 10
5Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: oligoisomaltose: FOS: xylo-oligosaccharide=5: 10: 5.
The composition weight proportioning of compound probiotic is: bifidobacterium longum: bifidobacterium breve: lactobacillus bulgaricus=2: 4: 3.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 6: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 68g
Desalted whey powder 37g
Granulated sugar 6g
Peanut oil 8g
Complex prebiotics 20g
Compound probiotic 1.0 * 10
11Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: chitosan oligomer: soyabean oligosaccharides: inulin: milk ketose=2: 4: 2: 10.
The composition weight proportioning of compound probiotic is: baby's fork bacillus: bifidobacterium breve: Lactobacillus casei=1: 5: 2.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 7: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 54g
Desalted whey powder 26g
Granulated sugar 4g
Peanut oil 6g
Complex prebiotics 2g
Compound probiotic 1.0 * 10
8Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: oligoisomaltose: xylo-oligosaccharide: inulin: chitosan oligomer=2: 2: 8: 10.
The composition weight proportioning of compound probiotic is: baby's fork bacillus: bifidobacterium longum: lactobacillus acidophilus=5: 1: 3.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Embodiment 8: prepare a kind of milk powder that adds symphysis unit, wherein, the prescription of milk powder is as follows:
Milk (material of giving money as a gift) 60g
Desalted whey powder 20g
Granulated sugar 5g
Peanut oil 5g
Complex prebiotics 10g
Compound probiotic 1.0 * 10
14Cfu
B B-complex 0.023g
Composite mineral matter 0.5g
Nucleotides 0.05g
Taurine 0.04g
DHA 0.15g
ARA 0.1g
Choline 0.1g
Lecithin 0.2g
Beta carotene 0.14g.
Wherein, the composition weight proportioning of complex prebiotics is: FOS: soyabean oligosaccharides: xylo-oligosaccharide: milk ketose=5: 2: 8: 10.
The composition weight proportioning of compound probiotic is: bifidobacterium adolescentis: bifidobacterium longum: lactobacillus thermophilus=1: 8: 4.
The prescription of B B-complex is with embodiment 1.
The prescription of composite mineral matter is with embodiment 1.
Preparation technology is with embodiment 1.
Test example 1: following animal experiment has been described the comparison that complex prebiotics among the present invention improves the result to improvement and the single prebiotics of rat gut flora.
1 materials and methods:
1.1 animal used as test: 64 of SPF level SD male rats (Jinan Ge Run zoopery scientific and technological development Co., Ltd provides), body weight 100 ± 10g is divided into 8 groups at random, 8 every group.
1.2 grouping:
Group 1: control group: the basal feed of feeding.
Group 2: single prebiotics: basal feed adds 4% oligoisomaltose.
Group 3: single prebiotics: basal feed adds 4% galactooligosaccharide.
Group 4: single prebiotics: basal feed adds 4% soyabean oligosaccharides.
Group 5: complex prebiotics: (weight proportion of each component of prebiotics is the complex prebiotics of basal feed interpolation 4%: xylo-oligosaccharide 2+ galactooligosaccharide 10+ inulin 15).
Group 6: complex prebiotics: (weight proportion of each component of prebiotics is the complex prebiotics of basal feed interpolation 4%: oligoisomaltose 15+ xylo-oligosaccharide 2+ gossypose 5).
Group 7: complex prebiotics: (weight proportion of each component of prebiotics is the complex prebiotics of basal feed interpolation 4%: soyabean oligosaccharides 10+ FOS 5+ xylo-oligosaccharide 2+ inulin 15).
Group 8: complex prebiotics: (weight proportion of each component of prebiotics is the complex prebiotics of basal feed interpolation 4%: oligoisomaltose 15+ gossypose 5+ milk ketose 10+ inulin 15).
Each group is raised free diet separately.The feed of feeding all is SPF level feeds, drinks water to be pure water.
1.3 sample collection: feeding time respectively was 3 weeks, forced method get the rat fresh excreta respectively at the 0th day, 3 days, 7 days, 10 days, 14 days, 21 days after the experiment beginning, be loaded on and weigh and be equipped with in the sterile test tube of physiological saline and bead, test tube behind the dress sample is weighed once more, tries to achieve sample weight.Build the pipe post-games and be placed on the liquid quick oscillation device and mix,, become series with physiological saline with 10 times ratio doubling dilution then to make even suspension.
1.4 medium preparation: adopt the aerobic culture medium EMB of selectivity, EC, selectivity anaerobic culture medium KV, TPY and MRS are according to the requirement preparation of " Clinical Anaerobic Bacteria inspection manual ".
1.5 inoculated and cultured: the sample series dilution 0.01ml that gets above-mentioned processing is inoculated on the culture medium, places anaerobism and aerobic environment to cultivate respectively.37 ℃ of aerobic cultivations, 24h observed result, observed result behind the anaerobism 48h.The record clump count is also made identification of strains.
1.6 calculate and data statistics: the result represents with logarithm value, computing formula: the viable bacteria colony in every gram ight soil is counted logarithm value=log{[sample weight (g)+dilution liquid measure (ml)]/sample weight * dilution factor * bacterium colony number * 100}.All data are all analyzed with the SPSS statistical software.
2 results:
Adopt the aerobic culture medium EMB of selectivity, EC respectively, selectivity anaerobic culture medium KV, TPY and MRS detect and respectively organize flora in the rat stool sample 5: enterobacteria, enterococcus, bacteroid, Bifidobacterium and lactobacillus, testing result sees Table 1-5.
Table 1 is respectively organized rat stool sample enterobacteria group testing result [x ± s, x=log (CFU/g), n=8]
Annotate: a1, b1, c1, d1, e1 represent to have compared significant difference between two groups, P＜0.05; A2, b2, c2 represent to have compared between two groups utmost point significant difference, P＜0.01.
Table 2 is respectively organized rat stool sample enterococcus group testing result [x ± s, x=log (CFU/g), n=8]
Annotate: a1, b1, c1, d1, e1 represent to have compared significant difference between two groups, P＜0.05; A2, b2, c2 represent to have compared between two groups utmost point significant difference, P＜0.01.
Table 3 is respectively organized rat stool sample bacteroid group testing result [x ± s, x=log (CFU/g), n=8]
Annotate: a1, b1 represent to have compared significant difference between two groups, P＜0.05.
Table 4 is respectively organized rat stool sample Bifidobacteria population testing result [x ± s, x=log (CFU/g), n=8]
Annotate: a1, b1, c1, d1, e1, f1, g1, h1 represent to have compared significant difference between two groups, P＜0.05; A2, b2, c2 represent to have compared between two groups utmost point significant difference, P＜0.01.
Table 5 is respectively organized rat stool sample lactobacillus group testing result [x ± s, x=log (CFU/g), n=8]
Annotate: a1, b1 represent to have compared significant difference between two groups, P＜0.05; A2 represents to have compared between two groups utmost point significant difference, P＜0.01.
Table 1, table 2 data all show, single prebiotics makes enterobacteria, enterococcus that the trend of minimizing be arranged, and that complex prebiotics reduces is more; Though table 3 shows the bacteroid of adding complex prebiotics the trend of minimizing is arranged, variation tendency is not obvious.Table 4, table 5 data show that compare with single prebiotics, complex prebiotics can make beneficial bacterium that good growth trend is arranged, but relative Bifidobacterium, the increase trend of lactobacillus is not clearly.
By above-mentioned test as can be seen, different prebioticses has very big difference to the influence of rat gut flora, and the complex prebiotics of various combination never is simple overlaying relation to the influence of rat gut flora, therefore, to add the complex prebiotics in the milk powder to be the complex prebiotics combination with optimum efficiency that obtains by test in the present invention.
Test example 2: following animal experiment described symphysis unit among the present invention to administration of antibiotics after rat recover the beneficial effect of beneficial bacterium advantage in the gut flora.
1 materials and methods:
1.1 animal used as test: 24 of SPF level SD male rats (Jinan Ge Run zoopery scientific and technological development Co., Ltd provides), body weight 100 ± 10g is divided into 3 groups at random, 8 every group.
1.2 grouping:
Group 1: control group: the basal feed of feeding
Group 2: experiment contrast group: the basal feed of feeding, 0 day administration of antibiotics (Lincomycin Hydrochloride, 200mg/Kg/ day, per os was irritated stomach) once
Group 3: experimental group: the basal feed of feeding, and administration of antibiotics, after 3 days, feeding, (weight proportion of each component of symphysis unit is the feed that adds 4% symphysis unit: xylo-oligosaccharide 2+ galactooligosaccharide 10+ soyabean oligosaccharides 10+ gossypose 5+ bifidobacterium infantis 10
3Cfu/g+ bifidobacterium adolescentis 10
2Cfu/g+ lactobacillus acidophilus 10
2Cfu/g)
1.3 sample collection: feeding time was 3 weeks, forced method get the rat fresh excreta respectively at the 0th, 3,7,14,21 day after the experiment beginning, be loaded on and weigh and be equipped with in the sterile test tube of physiological saline and bead, the test tube behind the dress sample is weighed once more, tries to achieve sample weight.Build the pipe post-games and be placed on the liquid quick oscillation device and mix,, become series with physiological saline with 10 times ratio doubling dilution then to make even suspension.
1.4 medium preparation: adopt the aerobic culture medium EMB of selectivity, EC, selectivity anaerobic culture medium KV, TPY and MRS are according to the requirement preparation of " Clinical Anaerobic Bacteria inspection manual ".
1.5 inoculated and cultured: the sample series dilution 0.01ml that gets above-mentioned processing is inoculated on the culture medium, places anaerobism and aerobic environment to cultivate respectively.37 ℃ of aerobic cultivations, 24h observed result, observed result behind the anaerobism 48h.The record clump count is also made identification of strains.
1.6 calculate and analyze: the result represents with various bacterium proportions
Computing formula:
Viable bacteria colony number in every gram ight soil=[sample weight (g)+dilution liquid measure (ml)]/sample weight * dilution factor * bacterium colony number
2 results:
Adopt the aerobic culture medium EMB of selectivity, EC respectively, selectivity anaerobic culture medium KV, TPY and MRS detect and respectively organize flora in the rat stool sample 5: enterobacteria, enterococcus, bacteroid, Bifidobacterium and lactobacillus, and calculate, testing result sees Table 6.
Table 6 symphysis unit is to the experimental result that influences of big gut flora
From experimental data as can be seen, the recovery of the rat gut flora of symphysis unit after for administration of antibiotics and beneficial bacterium advantage establishes good benefit.
Test example 3: following test has been described the baby formula milk powder of interpolation symphysis of the present invention unit to diarrhoea infant's clinical effectiveness takes place.
1 data and method
1.1 Object Selection: select in August, 2008-2008 year September, certain hospital-based outpatient pediatic clinic infantile diarrhea 120 example, 7 months-3 years old age.Clinical manifestation meets following characteristics: (1) sick first have slight upper respiratory tract infection symptoms (runny nose, idol are coughed), heating, vomiting; (2) stool is rare water sample or egg soup sample, do not have and smell as of rotten fish, and no purulence blood, number of times 24h surpasses more than 3 times; (3) the light or moderate dehydration of companion.
1.2 method: whole cases are divided into treatment at random organize 60 examples, control group 60 examples, the state of an illness, the course of disease are learned the processing no significant difference by statistics between two groups.
The treatment group: the baby milk powder among the edible embodiment 1, every day consumption 100g
Control group: dioctahedral smectite treatment, dosage: age＜1 year old is 1g, and 1～2 years old is 1～1.5g, and 2～3 years old is 2g, serve on 3d every day three times, normal diet (preventing to bring in the diet any probio or prebiotics composition)
1.3 the result judges: by the curative effect determinate standard that the sick meeting of national baby diarrhea is formulated, produce effects: refer to medication 24h-48h, times of defecation is less than 2 times/d or recovers normal number of times, and the stool proterties recovers normal, clinical symptom disappearance; Effectively: refer to medication 24h-72h, times of defecation is less than 2 times/d, and proterties takes a turn for the better, and moisture reduces, and clinical symptoms disappears substantially; Invalid: refer to 72h after the medication, stool does not have more than 2 times/d or proterties improves even the person that increases the weight of to change the medicine.Take effect slowly because of symphysis unit, its treatment time extended to for 1 week.
2 results: according to criterion, two groups result of treatment sees Table 7
Table 7 baby formula milk powder is to the result of treatment of infantile diarrhea
See that from result of the test the baby formula milk powder among the present invention has the curative effect the same with dioctahedral smectite to infantile diarrhea to find out.Baby milk powder is adjusted the balance of infant's gut flora by adding symphysis unit, suppresses the breeding of pathogenic bacteria, thereby reaches the therapeutic action to infantile diarrhea.Because this product is to come diarrhoea is prevented by diet, can not bring the side effect of chemicals such as dioctahedral smectite, has bigger advantage.
Claims (8)
1. a baby milk powder that adds symphysis unit is characterized in that, comprises following component: the fresh milk material of giving money as a gift, 40～68 grams; Desalted whey powder, 15～37 grams; Granulated sugar, 3～6 grams; Vegetable oil, 4～8 grams; Complex prebiotics, 0.4～20 gram; Compound probiotic 1.0 * 10
5～1.0 * 10
14Cfu;
Described complex prebiotics is one of following combination:
1. 3 parts+gossypose of 10 parts+xylo-oligosaccharide of oligoisomaltose is 5 parts;
2. 10 parts+inulin of 2 parts+galactooligosaccharide of xylo-oligosaccharide is 15 parts;
3. 2 parts+gossypose of 15 parts+xylo-oligosaccharide of oligoisomaltose is 5 parts;
4. 2 parts+inulin of 5 parts+xylo-oligosaccharide of 10 parts+FOS of soyabean oligosaccharides is 15 parts;
5. 10 parts+inulin of 5 parts+milk ketose of 15 parts+gossypose of oligoisomaltose is 15 parts;
Described umber is a weight portion;
Described compound probiotic is a kind of or several arbitrary proportions combination in bifidobacterium strains, lactobacillus strains, streptococcus bacterial strain, lactococcus bacterial strain, the Bacillus strain.
2. a kind of baby milk powder that adds symphysis unit according to claim 1 is characterized in that, also comprises following component: B B-complex, 0.023 gram; Composite mineral matter, 0.5 gram; Nucleotides, 0.05 gram; Taurine, 0.04 gram; DHA, 0.15 gram; Arachidonic acid, 0.1 gram; Lecithin, 0.2 gram; Beta carotene, 0.14 gram.
3. a kind of baby milk powder that adds symphysis unit according to claim 1 is characterized in that, the content of described complex prebiotics is 2～10 grams.
4. a kind of baby milk powder that adds symphysis unit according to claim 1 is characterized in that: described compound probiotic is the combination of bifidobacterium strains and lactobacillus strains.
5. a kind of baby milk powder that adds symphysis unit according to claim 4 is characterized in that: described bifidobacterium strains is bifidobacterium infantis or bifidobacterium adolescentis or bifidobacterium longum or bifidobacterium breve; Described lactobacillus strains is lactobacillus bulgaricus or lactobacillus acidophilus or lactobacillus thermophilus or Lactobacillus casei.
6. a kind of baby milk powder that adds symphysis unit according to claim 2 is characterized in that described B B-complex is composed of the following components: vitamin A, 4 grams; Vitamin D, 2 grams; Vitamin E, 0.1 gram; Vitamin K
1, 0.035 gram; Cobastab
1, 0.6 gram; Cobastab
2, 0.8 gram; Cobastab
6, 0.35 gram; Cobastab
12, 0.015 gram; Vitamin C, 2 grams; Niacinamide usp, 8 grams; Folic acid, 0.08 gram; Calcium pantothenate, 5 grams; Biotin, 0.02 gram.
7. a kind of baby milk powder that adds symphysis unit according to claim 2 is characterized in that described composite mineral matter is composed of the following components: ferrous lactate, 50 grams; Zinc lactate, 10 grams; Copper sulphate, 2 grams; Potassiumiodate, 0.13 gram; Calcium carbonate, 437.7 grams; Manganese sulfate, 0.17 gram.
8. the described a kind of preparation method who adds the baby milk powder of symphysis unit of claim 2, it is characterized in that, step is: mix other components except that compound probiotic, B B-complex, get mixed solution, use high pressure homogenizer under 10～20MPa, to carry out homogeneous then, carry out spray-drying or freeze drying then, get powder product, add compound probiotic, B B-complex then, mixing, vacuum packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102498088A CN101449708B (en) | 2008-12-29 | 2008-12-29 | Infant milk powder added with biostime and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102498088A CN101449708B (en) | 2008-12-29 | 2008-12-29 | Infant milk powder added with biostime and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101449708A CN101449708A (en) | 2009-06-10 |
| CN101449708B true CN101449708B (en) | 2011-08-10 |
Family
ID=40732339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102498088A Active CN101449708B (en) | 2008-12-29 | 2008-12-29 | Infant milk powder added with biostime and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101449708B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11975014B2 (en) | 2010-12-31 | 2024-05-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2569241T5 (en) * | 2010-01-19 | 2019-09-11 | Abbott Lab | A composition comprising Lactobacillus rhamnosus HN001 and prebiotics for use in the treatment of allergic lung disease |
| CN101810222A (en) * | 2010-04-23 | 2010-08-25 | 陕西农产品加工技术研究院 | Synbiotic goat milk powder |
| CN101810220B (en) * | 2010-04-23 | 2012-06-27 | 陕西农产品加工技术研究院 | Preparation method of synbiotic goat milk powder |
| CN101810223B (en) * | 2010-04-27 | 2012-03-21 | 李卫平 | Functional milky tea powder and preparation method thereof |
| CN101953403B (en) * | 2010-09-25 | 2012-05-23 | 澳优乳业（中国）有限公司 | Infant formula milk powder added with secretory immunoglobulin A and preparation method thereof |
| ES2708924T3 (en) | 2010-12-31 | 2019-04-12 | Abbott Lab | Procedures for the use of oligosaccharides in human milk to improve respiratory health of the respiratory tract |
| ES2667393T3 (en) | 2010-12-31 | 2018-05-10 | Abbott Laboratories | Oligosaccharides of human milk to modulate inflammation |
| EP2658399B2 (en) | 2010-12-31 | 2024-02-28 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides for use in treating and/or preventing enteric rotavirus infection |
| CN102144669B (en) * | 2011-04-14 | 2013-06-12 | 内蒙古蒙牛乳业（集团）股份有限公司 | DHASCO (docosahexaenoic acid single cell oil)-contained modulated milk and production method thereof |
| CN102422895A (en) * | 2011-11-29 | 2012-04-25 | 内蒙古伊利实业集团股份有限公司 | Fresh cheese for children and preparation method thereof |
| CN102415451B (en) * | 2011-12-08 | 2013-07-31 | 赵冰台 | Formula whey milk |
| CN102488012B (en) * | 2011-12-14 | 2015-01-28 | 北京东方联鸣科技发展有限公司 | Formula milk powder for calves |
| CN102511714B (en) * | 2011-12-21 | 2014-10-01 | 浙江康恩贝健康产品有限公司 | High-activity probiotic composition suitable for infants and preparation method thereof |
| CN103181459A (en) * | 2011-12-27 | 2013-07-03 | 北京资源亚太饲料科技有限公司 | Preparation method for feed synbiotics |
| CN103053691B (en) * | 2013-02-18 | 2014-07-23 | 杨凌圣妃乳业有限公司 | Baby formula goat milk powder and preparation method thereof |
| CN103125602A (en) * | 2013-02-21 | 2013-06-05 | 江西雄鹰乳业有限公司 | Enhancing functionalized infant formula milk powder |
| CN103404849A (en) * | 2013-07-08 | 2013-11-27 | 黄裕兵 | Internal-heat-removing chrysanthemum tea |
| CN103621633B (en) * | 2013-12-05 | 2015-02-04 | 刘保惠 | Infant series yak milk formula milk powder and preparation method thereof |
| CN103651857B (en) * | 2013-12-27 | 2016-03-09 | 光明乳业股份有限公司 | Containing the babies ' formula milk powder of probio, preparation method and storage method thereof |
| CN104170995A (en) * | 2014-07-15 | 2014-12-03 | 常熟市厚福堂健康服务有限公司 | Anti-allergy nutritional milk powder |
| CN104170983A (en) * | 2014-07-15 | 2014-12-03 | 常熟市厚福堂健康服务有限公司 | Desensitization nutrition milk powder |
| CN104170997A (en) * | 2014-07-15 | 2014-12-03 | 常熟市厚福堂健康服务有限公司 | Antiallergic nutritional milk powder |
| CN104304935A (en) * | 2014-10-08 | 2015-01-28 | 广东东泰乳业有限公司 | Infant formula rice flour improved through biotechnology and preparation method thereof |
| CN104489132A (en) * | 2014-12-26 | 2015-04-08 | 光明乳业股份有限公司 | Infant formula milk powder containing lactulose and preparation method |
| CN104705400A (en) * | 2015-03-30 | 2015-06-17 | 淮海工学院 | Processing process for fat replacing type yoghurt |
| CN105558059A (en) * | 2015-12-16 | 2016-05-11 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and preparation method thereof |
| CN106035674A (en) * | 2016-06-24 | 2016-10-26 | 吉林大学 | Prebiotics-added formula milk powder suitable for premature infants and infants with low birth weight and preparation method thereof |
| CN106720372B (en) * | 2016-11-23 | 2020-06-30 | 光明乳业股份有限公司 | Children formula milk powder, children formula milk powder set and preparation methods of children formula milk powder and children formula milk powder set |
| CN107668208A (en) * | 2017-11-13 | 2018-02-09 | 海普诺凯营养品有限公司 | A kind of formula milk for promoting intestinal health |
| CN108777998B (en) * | 2018-02-12 | 2022-03-11 | 天津天狮生物发展有限公司 | Composite prebiotics for regulating intestinal function of human body and application thereof |
-
2008
- 2008-12-29 CN CN2008102498088A patent/CN101449708B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11975014B2 (en) | 2010-12-31 | 2024-05-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101449708A (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101449708B (en) | Infant milk powder added with biostime and preparation method thereof | |
| CN101449830B (en) | Mid-aged milk powder added with biostime and preparation method thereof | |
| CN104206539A (en) | Probiotic-containing infant milk powder | |
| CN101299934B (en) | Nutritional formulation for promoting catch-up growth | |
| CN103889240B (en) | For increasing insulin sensitivity and/or reducing the compositions of insulin resistance | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN106794207A (en) | Using lactobacillus reuteri in life early recovery micropopulation ecological disturbance | |
| US20190069586A1 (en) | Food Compositions for Weaning | |
| RU2541396C2 (en) | Nutritional compositions | |
| CN103582426A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
| CN107019701A (en) | The method that the incidence of disease of the necrotizing enterocolitis of baby, child or children is reduced using human milk oligosaccharides | |
| CN102325458A (en) | Prevention and treatment of rotavirus diarrhoea | |
| CN105792673A (en) | Use of nutritional compositions having a low protein amount | |
| TW200911278A (en) | Reduction of risk of diarrhoea | |
| CN103347405A (en) | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk | |
| WO2011120929A2 (en) | Animal feed for calves for conditioning the intestinal flora | |
| CN108740251A (en) | A kind of probiotic gel candy and preparation method thereof improving constipation | |
| CN107712050A (en) | One kind addition sialic acid and digestible premature labor baby milk powder and preparation method thereof | |
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| JP2014196339A (en) | Composition for prevention or treatment of anemia | |
| CN105249480A (en) | Chewable tablet with dietary fiber and bifidobacteria and preparing method thereof | |
| CN109561723A (en) | For preventing, treating the alimentation composition and infant formula of the mixture comprising oligosaccharide and optionally bifidobacterium lactis of non-rotavirus induced diarrhea or reduction its severity | |
| CN100482104C (en) | Process for preparing lactic acid bacteria oral liquor | |
| CN108523136A (en) | A kind of composition containing lactase | |
| US9861654B2 (en) | Treatment of diarrhea and post-weaning diarrhea with resistant potato starch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20180312 Granted publication date: 20110810 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20210312 Granted publication date: 20110810 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20210312 Granted publication date: 20110810 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20230307 Granted publication date: 20110810 |